Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC S versus ESMOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC S versus ESMOLOL HYDROCHLORIDE.
BETOPTIC S vs ESMOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Instill 1 drop in the affected eye(s) twice daily.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min; titrate by 25-50 mcg/kg/min every 5-10 minutes up to 200 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Terminal elimination half-life: approximately 9 minutes in adults (range 4–13 min); in patients with hepatic impairment: unchanged; in severe renal impairment: prolonged to 12–20 min due to metabolite accumulation. Clinically, rapid offset (within 20–30 min) allows for titration.
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Rapid metabolism by red blood cell esterases to inactive acid metabolite (ASL-8123) and methanol; <2% excreted unchanged in urine; primarily renal elimination of metabolites.
Category C
Category A/B
Beta-Blocker
Beta-Blocker